UNASSIGNED: OBJECTIVE @entity5576 ( @entity5576 ) may cause @entity1939 due to @entity428 ( @entity428 ). @entity50 has been identified in select @entity1 , leading to stenting as a potential treatment, but its effects on global @entity428 have not been completely defined. The purpose of this pilot study was to assess the effects of @entity50 stenting on @entity428 in a small group of @entity1 with @entity5576 . METHODS Ten @entity1 for whom medical therapy had failed were prospectively followed. Ophthalmological examinations were assessed, and @entity1 with @entity50 on MR angiography proceeded to catheter angiography, venography with assessment of pressure gradient, and @entity428 monitoring. @entity1 with @entity428 measurements and an elevated pressure gradient across the @entity850 were treated with stent placement. RESULTS All @entity1 had elevated venous pressure (mean 39.5    14.9 mm Hg), an elevated gradient across the @entity50 (30.0    13.2 mm Hg), and @entity428 (42.2    15.9 mm Hg). Following stent placement, all @entity1 had resolution of the @entity850 and gradient (1    1 mm Hg). The @entity428 values showed an immediate decrease (to a mean of 17.0    8.3 mm Hg), and further decreased overnight (to a mean of 8    4.2 mm Hg). All @entity1 had subjective and objective improvement, and all but one improved during follow-up (median 23.4 months; range 15.7-31.6 months). Two @entity1 developed stent-adjacent @entity850 ; retreatment abolished the @entity850 and gradient in both cases. @entity1 presenting with @entity1829 had resolution on follow-up funduscopic imaging and optical coherence tomography (OCT) and improvement on visual field testing. @entity1 presenting with @entity1952 had optic nerve thinning on follow-up OCT, but improved visual fields. CONCLUSIONS For selected @entity1 with @entity5576 and @entity50 with an elevated pressure gradient and @entity428 , @entity50 stenting results in resolution of the venous pressure gradient, @entity551 , and functional, neurological, and ophthalmological improvement. As @entity1 are at risk for stent-adjacent @entity850 , further follow-up is necessary to determine long-term outcomes and gain an understanding of @entity50 as a primary or secondary pathological process behind @entity428 .

XXXX stenting for reduction of @entity428 in @entity5576 : a prospective pilot study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1952 :: ('MESH:D009896', 'Disease') :: ['optic atrophy'] @entity428 :: ('MESH:D019586', 'Disease') :: ['elevated intracranial pressure', 'ICP', 'elevated ICP'] @entity1939 :: ('MESH:D001766', 'Disease') :: ['blindness'] @entity1829 :: ('MESH:D010211', 'Disease') :: ['papilledema'] @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis'] @entity551 :: ('MESH:D007022', 'Disease') :: ['reduction in ICP'] @entity50 :: ('MESH:D012851', 'Disease') :: ['venous sinus', 'Venous sinus stenosis', 'venous sinus stenosis'] @entity5576 :: ('MESH:D011559', 'Disease') :: ['Idiopathic intracranial hypertension', 'IIH']
@entity50 :: (MESH:D012851,Disease) :: ['Venous sinus']
